Amneal to Virtually Participate at Upcoming Investor Conferences

Rhea-AI Summary

Amneal Pharmaceuticals (NYSE: AMRX) announced its participation in two upcoming investor conferences: the Raymond James Institutional Investors Conference on March 1, 2021, at 3:00 p.m. ET, and the Barclays Global Healthcare Conference on March 10, 2021, at 4:10 p.m. ET. Both events will include fireside chats and can be accessed via a live webcast on the Company's Investor Relations website. Amneal focuses on developing and distributing generic and specialty pharmaceuticals, boasting around 250 product families, and operates globally, including a majority stake in AvKARE, which supplies pharmaceuticals to government agencies.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that its management team will virtually attend the following investor conferences:

Raymond James Institutional Investors Conference
March 1, 2021
Fireside Chat – 3:00 p.m. Eastern Time

Barclays Global Healthcare Conference
March 10, 2021
Fireside Chat – 4:10 p.m. Eastern Time

A live webcast of the presentations will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. A replay of the webcast will be posted shortly after the call and will be available for a limited time following the event.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

Amneal has an extensive portfolio of approximately 250 product families and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas. The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.

The Company also owns 65% of AvKARE. AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs. AvKARE is also a packager and wholesale distributor of pharmaceuticals and vitamins to its retail and institutional customers who are located throughout the United States focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing. For more information, visit www.amneal.com.

Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995, as amended). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including, among other things, future operating results and financial performance, product development and launches, integration strategies and resulting cost reduction, market position and business strategy. Words such as “may,” “will,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “assume,” “continue,” and similar words are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Amneal. A list and descriptions of these risks, uncertainties and other factors can be found in the Company’s most recently filed Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as supplemented by any subsequently filed Quarterly Reports on Form 10-Q. Copies of these filings are available online at www.sec.gov, www.amneal.com or upon request from the Company. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof, except as otherwise required by United States securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005673/en/

FAQ

What is the schedule for Amneal Pharmaceuticals' upcoming investor conferences in 2021?

Amneal Pharmaceuticals will participate in the Raymond James Institutional Investors Conference on March 1, 2021, at 3:00 p.m. ET, and the Barclays Global Healthcare Conference on March 10, 2021, at 4:10 p.m. ET.

How can I access the live webcast of Amneal Pharmaceuticals' investor presentations?

The live webcast of the presentations can be accessed through the Investor Relations section of Amneal Pharmaceuticals' website at https://investors.amneal.com.

What type of products does Amneal Pharmaceuticals focus on?

Amneal Pharmaceuticals specializes in the development and distribution of generic and specialty drug products, with an extensive portfolio of approximately 250 product families.

What is AvKARE and what role does it play in Amneal Pharmaceuticals' operations?

AvKARE is a subsidiary of Amneal Pharmaceuticals, providing pharmaceuticals and medical products primarily to governmental agencies, focusing on the Department of Defense and the Department of Veterans Affairs.

What are the main therapeutic areas Amneal Pharmaceuticals targets?

Amneal Pharmaceuticals focuses on a variety of therapeutic areas, including central nervous system and endocrine disorders, as well as expanding into complex dosage forms like biosimilars.